Do analysts prefer SNOA or SCYX?

SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 528.27%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to SNOA or SCYX?

In the previous week, Sonoma Pharmaceuticals and Sonoma Pharmaceuticals both had 1 articles in the media. SCYNEXIS's average media sentiment score of 0.00 beat Sonoma Pharmaceuticals' score of -0.52 indicating that SCYNEXIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonoma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative SCYNEXIS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SNOA or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer ALLR or SNOA?

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 1 articles in the media. Allarity Therapeutics' average media sentiment score of 0.50 beat Sonoma Pharmaceuticals' score of -0.52 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sonoma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate VYNE or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate MDCX or SNOA?

Medicus Pharma presently has a consensus target price of $9.00, indicating a potential upside of 1,856.52%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Medicus Pharma is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer MDCX or SNOA?

In the previous week, Medicus Pharma had 3 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 4 mentions for Medicus Pharma and 1 mentions for Sonoma Pharmaceuticals. Medicus Pharma's average media sentiment score of 1.05 beat Sonoma Pharmaceuticals' score of -0.52 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sonoma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Sonoma Pharmaceuticals (SNOA) Competitors

$1.14 -0.02 (-1.72%)

Closing price 06/23/2026 03:59 PM Eastern

Extended Trading

$1.16 +0.02 (+1.67%)

As of 07:00 AM Eastern

Compare

SNOA vs. SCYX, ALVR, ALLR, VYNE, and MDCX

Should you buy Sonoma Pharmaceuticals stock or one of its competitors? MarketBeat compares Sonoma Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sonoma Pharmaceuticals include SCYNEXIS (SCYX), AlloVir (ALVR), Allarity Therapeutics (ALLR), VYNE Therapeutics (VYNE), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.

How does Sonoma Pharmaceuticals compare to SCYNEXIS?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Sonoma Pharmaceuticals has a net margin of -16.26% compared to SCYNEXIS's net margin of -41.79%. Sonoma Pharmaceuticals' return on equity of -43.95% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Sonoma Pharmaceuticals has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A
SCYNEXIS	$20.60M	1.84	-$8.61M	-$3.84	N/A

Sonoma Pharmaceuticals has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 528.27%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sonoma Pharmaceuticals and Sonoma Pharmaceuticals both had 1 articles in the media. SCYNEXIS's average media sentiment score of 0.00 beat Sonoma Pharmaceuticals' score of -0.52 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sonoma Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 2.3% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

SCYNEXIS beats Sonoma Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to AlloVir?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Sonoma Pharmaceuticals and 0 mentions for AlloVir. AlloVir's average media sentiment score of 0.00 beat Sonoma Pharmaceuticals' score of -0.52 indicating that AlloVir is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Negative
AlloVir	Neutral

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 2.3% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sonoma Pharmaceuticals has higher revenue and earnings than AlloVir. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

AlloVir has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. Sonoma Pharmaceuticals' return on equity of -43.95% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%
AlloVir	N/A	-71.03%	-61.27%

Sonoma Pharmaceuticals has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Sonoma Pharmaceuticals beats AlloVir on 8 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 1 articles in the media. Allarity Therapeutics' average media sentiment score of 0.50 beat Sonoma Pharmaceuticals' score of -0.52 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sonoma Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Sonoma Pharmaceuticals has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	65.63	-$11.23M	-$0.72	N/A
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A

Allarity Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Allarity Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. Sonoma Pharmaceuticals' return on equity of -43.95% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

Allarity Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 676.52%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Allarity Therapeutics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Allarity Therapeutics beats Sonoma Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Sonoma Pharmaceuticals has a net margin of -16.26% compared to VYNE Therapeutics' net margin of -4,726.21%. Sonoma Pharmaceuticals' return on equity of -43.95% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

Sonoma Pharmaceuticals has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	38.03	-$26.48M	-$0.38	N/A
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A

VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for Sonoma Pharmaceuticals and 0 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 0.00 beat Sonoma Pharmaceuticals' score of -0.52 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
Sonoma Pharmaceuticals	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

VYNE Therapeutics and Sonoma Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by company insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Medicus Pharma had 3 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 4 mentions for Medicus Pharma and 1 mentions for Sonoma Pharmaceuticals. Medicus Pharma's average media sentiment score of 1.05 beat Sonoma Pharmaceuticals' score of -0.52 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sonoma Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Medicus Pharma presently has a consensus target price of $9.00, indicating a potential upside of 1,856.52%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Medicus Pharma is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Medicus Pharma has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Sonoma Pharmaceuticals has higher revenue and earnings than Medicus Pharma. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A

Medicus Pharma has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. Sonoma Pharmaceuticals' return on equity of -43.95% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

Summary

Medicus Pharma beats Sonoma Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNOA vs. The Competition

Export

Metric	Sonoma Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.55M	$2.96B	$6.45B	$12.38B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-0.60	18.43	24.66	23.99
Price / Sales	0.28	324.90	526.33	107.23
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	1.75	4.11	10.72	6.50
Net Income	-$3.17M	$64.45M	$3.56B	$336.88M
7 Day Performance	-0.87%	1.41%	0.94%	-0.16%
1 Month Performance	3.64%	1.04%	0.36%	0.76%
1 Year Performance	-60.82%	23.88%	29.67%	28.49%

Sonoma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNOA Sonoma Pharmaceuticals	0.2589 of 5 stars	$1.14 -1.7%	N/A	-61.2%	$5.55M	$19.53M	N/A	180
SCYX SCYNEXIS	1.7428 of 5 stars	$3.96 -3.1%	$24.00 +505.4%	-34.6%	$22.15M	$20.60M	N/A	60	News Coverage Gap Down
ALVR AlloVir	N/A	$4.37 +2.3%	N/A	+83.3%	$22.04M	N/A	N/A	110	High Trading Volume
ALLR Allarity Therapeutics	2.406 of 5 stars	$1.35 -5.9%	$10.25 +661.5%	+46.7%	$21.48M	$320K	N/A	10	Gap Down
VYNE VYNE Therapeutics	0.945 of 5 stars	$0.64 +0.5%	N/A	-28.9%	$21.21M	$454K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNOA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. SCYX, ALVR, ALLR, VYNE, and MDCX

How does Sonoma Pharmaceuticals compare to SCYNEXIS?

Summary

How does Sonoma Pharmaceuticals compare to AlloVir?

Summary

How does Sonoma Pharmaceuticals compare to Allarity Therapeutics?

Summary

How does Sonoma Pharmaceuticals compare to VYNE Therapeutics?

Summary

How does Sonoma Pharmaceuticals compare to Medicus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. SCYX, ALVR, ALLR, VYNE, and MDCX

How does Sonoma Pharmaceuticals compare to SCYNEXIS?

Is SNOA or SCYX more profitable?

Which has better valuation and earnings, SNOA or SCYX?

Which has more volatility & risk, SNOA or SCYX?

Do analysts prefer SNOA or SCYX?

Does the media refer more to SNOA or SCYX?

Do institutionals & insiders have more ownership in SNOA or SCYX?

Summary

How does Sonoma Pharmaceuticals compare to AlloVir?

Does the media prefer SNOA or ALVR?

Do insiders and institutionals hold more shares of SNOA or ALVR?

Which has stronger valuation and earnings, SNOA or ALVR?

Is SNOA or ALVR more profitable?

Which has more risk and volatility, SNOA or ALVR?

Do analysts recommend SNOA or ALVR?

Summary

How does Sonoma Pharmaceuticals compare to Allarity Therapeutics?

Does the media prefer ALLR or SNOA?

Which has better earnings & valuation, ALLR or SNOA?

Which has more volatility and risk, ALLR or SNOA?

Is ALLR or SNOA more profitable?

Do analysts recommend ALLR or SNOA?

Do insiders & institutionals hold more shares of ALLR or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to VYNE Therapeutics?

Is VYNE or SNOA more profitable?

Which has stronger earnings and valuation, VYNE or SNOA?

Which has more volatility and risk, VYNE or SNOA?

Does the media refer more to VYNE or SNOA?

Do analysts rate VYNE or SNOA?

Do insiders and institutionals have more ownership in VYNE or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Medicus Pharma?

Do insiders & institutionals believe in MDCX or SNOA?

Does the media prefer MDCX or SNOA?

Do analysts rate MDCX or SNOA?

Which has more volatility & risk, MDCX or SNOA?

Which has preferable valuation and earnings, MDCX or SNOA?

Is MDCX or SNOA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools